Intravitreal avastin: the low cost alternative to lucentis?

Am J Ophthalmol. 2006 Jul;142(1):141-3. doi: 10.1016/j.ajo.2006.03.036.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Drug Costs
  • Fluorescein Angiography
  • Humans
  • Injections
  • Macular Degeneration / complications
  • Macular Degeneration / diagnosis
  • Macular Degeneration / drug therapy*
  • Ranibizumab
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab